Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $411.3 million.

  • Apellis Pharmaceuticals' Cash & Equivalents rose 20.75% to $479.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.2 million, marking a year-over-year increase of 20.75%. This contributed to the annual value of $411.3 million for FY2024, which is 17.11% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Cash & Equivalents stood at $411.3 million for FY2024, which was up 17.11% from $351.2 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Cash & Equivalents registered a high of $640.2 million during FY2021, and its lowest value of $351.2 million during FY2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $411.3 million (2024), whereas its average is $438.1 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Cash & Equivalents crashed by 36.36% in 2023, and later grew by 17.11% in 2024.
  • Apellis Pharmaceuticals' Cash & Equivalents (Yearly) stood at $565.8 million in 2020, then rose by 13.15% to $640.2 million in 2021, then fell by 13.81% to $551.8 million in 2022, then slumped by 36.36% to $351.2 million in 2023, then grew by 17.11% to $411.3 million in 2024.